Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Silence Therapeutics Plc - American Depository Share
(NQ:
SLN
)
5.345
+0.145 (+2.79%)
Streaming Delayed Price
Updated: 1:37 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silence Therapeutics Plc - American Depository Share
< Previous
1
2
3
Next >
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Leadership Changes
December 15, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
November 12, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 06, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
October 23, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in September Investor Conferences
September 02, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 07, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
June 12, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 08, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
May 06, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
March 05, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
February 13, 2025
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
November 18, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
August 27, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 15, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
June 27, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
June 24, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
June 20, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
May 16, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
April 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
April 29, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
April 08, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
